The Evolution of Radiopharmaceuticals  

Changing the world of targeted alpha therapeutics and cancer treatment

Targeted Alpha

Therapeutics

Fusion’s R&D team has developed ways to connect alpha emitting medical isotopes to molecules which selectively target biomarkers found on the surface of cancer cells.

About us
Targeted Alpha Therapeutics

The Science Behind

Targeted Alpha

Therapies

Alpha particles emitted from medical isotopes can be used to kill cancer cells by creating lethal, double stranded DNA breaks. Unlike most radiation therapies, alpha particles travel only one to three cell lengths, thereby creating the means to selectively kill tumor cells.

At Fusion Pharma, we’re harnessing this potent and precise cell killing strategy to treat cancers via “targeted alpha therapeutics.”

Proprietary Fast-Clear™ Technology

The Fusion Advantage

A Safer Approach

to Targeted Radiopharmaceuticals

Our team is dedicated to improving the lives of cancer patients and positively impacting patients’ families and the community.

We created a proprietary linker to connect cancer-seeking molecules and alpha emitting medical isotopes. The Fast-Clear™ linker was specifically engineered to improve the safety of radiopharmaceuticals by helping the drug clear from normal, healthy tissues.

The Fusion Advantage

Our Manufacturing

Expertise

As we are a spin-out of a leading manufacturer and distributor of radiopharmaceuticals, the Centre for Probe Development and Commercialization (CPDC), we have experience building a robust supply chain. At Fusion, we develop targeted alpha therapeutics with the forethought of scale-up and reliable commercial production to meet the needs of the global market.